The Endocrine Society Issues Guidelines to Restrict Hormone Disorders in Children


Researchers from The Endocrine Society issued a Clinical Practice Guidelines for diagnosis and treatment of endocrine disorders to avoid hormone disorders

According to National Center for Biotechnology Information and National Institutes of Health (NCBI- NIH), the current five-year survival rates exceed 80 percent in childhood cancer. However, these children might suffer various medical complications after cancer treatment ends. NCBI- NIH further stated that a large number of the survivors could develop an endocrine disorder over their lifetime. Endocrine disorders are most evident among this population due to exposure to radiation therapy.  The committee led by Charles A. Sklar, M.D., of the Memorial Sloan Kettering Cancer Center in New York suggested best practices for restricting the growth of endocrine disorders among children.  The committee advised regular screening of the children who underwent radiation therapy to the brain. In the wake of diagnosing hormone disorder and several such conditions, the committee stated to treat these survivors with the same approaches as other patients who develop endocrine conditions. The Endocrine Society established the Clinical Practice Guideline Program with a goal to manage endocrine disorders with evidence-based recommendations. The task of creating these guidelines is handled by a writing committee of topic-related experts in the field.  This committee depends on the evidence-based reviews of the literature in the development of guideline recommendations. The Endocrine Society runs on society funds and no corporate interference is tolerated.

The guidelines were co-sponsored by the European Society of Endocrinology and the Pediatric Endocrine Society and endorsed by Pituitary Society. It was published as -Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, online in the Journal of Clinical Endocrinology & Metabolism (JCEM) on June 29, 2018.


Comments are closed.